NICORETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NICORETTE (NICORETTE).
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.
| Metabolism | Primarily hepatic metabolism via CYP2A6; also metabolized by glucuronidation. Major metabolite is cotinine. |
| Excretion | Nicotine is extensively metabolized in the liver, primarily to cotinine. Renal excretion accounts for 2-35% of nicotine elimination unchanged, depending on urine pH (acidic urine increases excretion). Biliary/fecal excretion is minimal (<5%). Total clearance is about 1 L/min, with renal clearance of about 100 mL/min. |
| Half-life | The terminal elimination half-life of nicotine is approximately 2 hours. This short half-life necessitates frequent dosing or continuous delivery to maintain therapeutic levels. Cotinine, the major metabolite, has a half-life of 15-20 hours. |
| Protein binding | Nicotine is <5% bound to plasma proteins, primarily albumin. It is a weak base with high volume of distribution, so protein binding is minimal. |
| Volume of Distribution | Nicotine has a large volume of distribution, ranging from 2.0 to 3.0 L/kg, reflecting extensive tissue uptake (including brain, lungs, and muscle). This accounts for its rapid distribution and large total body load. |
| Bioavailability | Transdermal patch: approximately 68-75% of the nicotine dose is absorbed systemically. Gum: about 50% due to buccal absorption and first-pass metabolism (swallowed portion is less bioavailable). Inhaler: approximately 50% of the dose is absorbed (buccal and pulmonary). Lozenge: similar to gum, about 50%. |
| Onset of Action | Inhalation: seconds to minutes via buccal mucosa absorption (nicotine inhaler). Transdermal (patch): 2-4 hours to reach plateau, with clinical effects appearing gradually. Gum/lozenge: 15–30 minutes to peak plasma concentration; clinical effects begin within minutes. |
| Duration of Action | Transdermal (patch): 24 hours with steady-state levels; gum/lozenge: 1–2 hours per dose; inhaler: rapid decline after use. The short half-life of nicotine means symptoms of withdrawal may return within hours without redosing. |
Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.
| Dosage form | GUM, CHEWING |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 mL/min): use with caution; nicotine elimination may be prolonged, but no specific dose adjustment guidelines are established. Monitor for adverse effects. |
| Liver impairment | No specific dose adjustment guidelines for Child-Pugh classes A or B. For severe hepatic impairment (Child-Pugh class C): use with caution; nicotine clearance may be reduced, and therapy should be initiated at the lowest effective dose with close monitoring. |
| Pediatric use | Not recommended for use in patients under 18 years of age for smoking cessation due to lack of safety and efficacy data. In adolescents (12-17 years) who are highly nicotine dependent, off-label use may be considered with careful dose titration: patch 14-21 mg/24h for heavy smokers, or gum 2-4 mg every 1-2 hours as needed. Close monitoring for adverse effects required. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NICORETTE (NICORETTE).
| Breastfeeding | Nicotine is excreted into breast milk; the M/P ratio is approximately 2.9. Infant exposure can cause adverse effects such as irritability, feeding difficulties, and apnea. Breastfeeding is generally not recommended during nicotine replacement therapy; if used, the lowest effective dose should be chosen and timing adjusted to minimize infant exposure (e.g., feed just before using the product). |
| Teratogenic Risk | Nicotine is a known teratogen. First trimester: Increased risk of spontaneous abortion and congenital anomalies, particularly cardiovascular and musculoskeletal defects. Second and third trimesters: Associated with fetal growth restriction, preterm birth, and stillbirth. Nicotine causes placental vasoconstriction, reducing uteroplacental perfusion. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to nicotine or any component of the formulation","Life-threatening arrhythmias (with transdermal patch, but caution with other formulations)","Pregnancy (category D; however, benefit may outweigh risk in some cases)","Active smoking while using Nicorette (should completely stop smoking before starting)"]
| Precautions | ["Nicotine replacement therapy should be used with caution in patients with cardiovascular disease, including arrhythmias and angina.","May cause adverse effects in patients with uncontrolled hypertension or hyperthyroidism.","Use caution in patients with peptic ulcer disease or severe renal impairment.","Concomitant smoking while using Nicorette increases risk of nicotine toxicity."] |
Loading safety data…
| Geriatric use |
| No specific dose adjustment required; however, elderly patients may have comorbidities or concurrent medications that require cautious use. Start with the lowest effective dose (e.g., 7 mg patch or 2 mg gum) and titrate based on tolerance and nicotine dependence. Monitor for adverse effects such as dizziness, hypotension, and arrhythmias due to age-related changes in drug clearance. |
| Fetal Monitoring | Regular monitoring of fetal growth and well-being via ultrasound for growth restriction, placental assessment, and fetal heart rate monitoring. Maternal monitoring includes blood pressure, heart rate, and signs of nicotine toxicity. Consider serial growth scans and biophysical profiles in the third trimester. |
| Fertility Effects | Nicotine may impair female fertility by altering tubal function, ovulation, and implantation. In males, nicotine can reduce sperm count, motility, and increase morphological abnormalities. Effects are generally reversible upon cessation. |